Online citations, reference lists, and bibliographies.
← Back to Search

Safety, Effectiveness, And Duration Of Effect Of BOTOX After Switching From Dysport For Blepharospasm, Cervical Dystonia, And Hemifacial Spasm

K. Bihari
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
ABSTRACT Background: Local injection of botulinum toxin type A is first-line treatment of blepharospasm, cervical dystonia, and hemifacial spasm; however, there is uncertainty about the optimal dose of toxin for each indication as well as dose-conversion ratios that should be used when switching products in clinical practice. Objective: The goal of this study was to compare the safety, effectiveness, and duration of clinical effect of BOTOX* and Dysport† after drug switching (Dysport to BOTOX) among patients with movement disorders. * BOTOX is a registered trade name of Allergan, Irvine, CA, USA † Dysport is a registered trade name of Ipsen Limited, Slough, UK Methods: A total of 48 patients diagnosed with blepharospasm (n = 27), cervical dystonia (n = 12), or hemifacial spasm (n = 9) were evaluated during a single-arm, crossover-design study in which each patient was his/her own historical control using a 5:1 or 4:1 conversion ratio of Dysport to BOTOX units. Patients were assessed (using Jankovic, Visual Analog Scale, general pain scale, Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] scores) after the last injection of Dysport and the first injection of BOTOX. Moreover, each patient kept a diary during treatment to track onset and duration of therapeutic effect. Results: Although BOTOX and Dysport were both clinically effective, this effect was more significant with BOTOX compared to Dysport based on TWSTRS for cervical dystonia ( p = 0.012), and Jankovic scores for blepharospasm ( p = 0.006). Longer duration of effect also was noted with BOTOX than with Dysport (blepharospasm, 62.2 days vs 47.4 days ( p = 0.001); cervical dystonia, 64.3 days vs 44.6 days ( p = 0.014); hemifacial spasm, 65.1 days vs 41.8 days ( p < 0.014), respectively). Of the 48 patients, 19 experienced at least one adverse drug reaction (ADR) during Dysport treatment, with the most commonly reported ADRs being ptosis for blepharospasm and hemifacial spasm and neck weakness for cervical dystonia. No patient reported an ADR during BOTOX treatment. Conclusions: Results suggest therapeutic effectiveness is enhanced with BOTOX compared to Dysport at a dosing ratio between 5:1 and 4:1 (Dysport:BOTOX). Safety and duration of therapeutic effect also are enhanced with BOTOX. Further research is needed.
This paper references
Potency equivalence of botulinum toxin preparations.
P. Hambleton (1994)
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia
W. Poewe (2002)
NZ: Ipsen
DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
C. Sampaio (1997)
Comparison of dosage effects between the American and the British botulinum toxin A product in the treatment of spasmodic dysphonia
R Whurr (1995)
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®
W. Poewe (1998)
Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia
D. Dressler (2002)
Clinical bioequivalence of the current commercial preparations of botulinum toxin
F. Durif (1995)
Low-Dose Botulinum Toxin-A Treatment of Cervical Dystonia – A Double-Blind, Randomized Pilot Study
U. Laubis-Herrmann (2002)
Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm
Zita Nüβgens (2004)
Dose standardisation of botulinum toxin
E. Schantz (1990)
A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia
T. Odergren (1998)
Dose standardisation of botulinum toxin.
M. Marion (1995)
Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm
Zita Niiligens (1997)
Botulinum A toxins: units versus units
K. Wohlfarth (1997)
A double‐blind, randomized, comparative study of Dysport® vs. Botox® in primary palmar hyperhidrosis
M. Simonetta Moreau (2003)
Long‐term efficacy of botulinum toxin A in treatment of various movement disorders over a 10‐year period
G. Hsiung (2002)

This paper is referenced by
Undesirable Distant Effects Following Botulinum Toxin Type A Injection
N. Roche (2008)
Pharmacology, Immunology and Current Developments
Kunio Aoki (2006)
Becoming An Injector: How One Practice Did It Successfully Physician Approach, Nurse Perspective
Molly Katz (2013)
Mediterranean anemia Lady health workers : A positive step towards women health in Pakistan
A. Casale ()
Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers
K. Wohlfarth (2008)
Chapter 33 – Comparative Clinical Trials of Botulinum Toxins
D. Dressler (2009)
[Botulinum toxin therapy for focal dystonia].
K. Hahn (2009)
Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study
P. Latino (2017)
Ultrasound-guided botulinum toxin A injection in the treatment of belly dancer’s dyskinesia
A. Alshubaili (2016)
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
Avram Fraint (2016)
To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study.
K. Tedroff (2018)
Efficacy of botulinum toxin A for treatment of unilateral spasms of the eyelid and its prognosis.
Y. Xu (2013)
Current awareness: Pharmacoepidemiology and drug safety
Botulinum toxin A is effective to treat tension-type headache caused by hemifacial spasm
A. Mizuma (2017)
EFNS guidelines on diagnosis and treatment of primary dystonias
Alberto Albanese (2011)
Diagnosis and Treatment of Primary (Idiopathic) Dystonia
Alberto Albanese (2010)
Botulinum Toxin Use in the Lower Urinary Tract
S. Morrisroe (2007)
Les différentes toxines botuliques et leurs spécificités
C. Beylot (2009)
OnabotulinumtoxinA (Botox®) and AbobotulinumtoxinA (Dysport®) in Treating Essential Blepharospasm: Long Term Results
Fadime Nuhoğlu (2016)
Botulinum neurotoxin — from laboratory to bedside
K. Foster (2009)
Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience
I. Farinelli (2006)
OnabotulinumtoxinA ( Botox ® ) and AbobotulinumtoxinA ( Dysport ® )
Fatma Esin Özdemir (2016)
Advances in Facial Rejuvenation: Botulinum Toxin Type A, Hyaluronic Acid Dermal Fillers, and Combination Therapies–-Consensus Recommendations
J. Carruthers (2008)
Botulinum Toxin Formulation , Concentration and Treatment
B. Karlsson (2012)
Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis.
J. Meijer (2008)
Efficacy of Botulinum Toxin Injections in the Treatment of Various Types of Facial Region Disorders
A. Çoban (2012)
Comparing two botulinum toxin type A formulations using manufacturers’ product summaries
R. Wenzel (2007)
Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement
Alberto Albanese (2015)
Botulinum toxin injections for the treatment of hemifacial spasm over 16years
M. Sorgun (2015)
Hemifacial spasm: a neurosurgical perspective.
Doo-sik Kong (2007)
Tratamento da distonia cervical com fisioterapia: estudo de 20 casos
M. Queiroz (2012)
What Practical Tips Can I Suggest during Botulinum Toxin Injection?
Woong-Woo Lee (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar